Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | HTR7 | P34969 | 2/20 | 0.66 |
| ▸ | HTR1A | P08908 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL336262 | 1.00 | SIRT6 (1.00) | SIRT6ADRB1MAPTHTR7HTR1A | |
| Hydrochloric Acid SCHEMBL1814630 | 0.98 | SIRT6 (0.96) | SIRT6ADRB1MAPTHTR7HTR1A | |
| Hydrogen Sulfide SCHEMBL28002215 | 0.98 | SIRT6 (0.96) | SIRT6ADRB1MAPTHTR7HTR1A | |
| SCHEMBL6152151 | 0.98 | SIRT6 (0.96) | SIRT6ADRB1MAPTHTR7HTR1A | |
| SCHEMBL6151805 | 0.98 | SIRT6 (0.96) | SIRT6ADRB1MAPTHTR7HTR1A | |
| SCHEMBL1496058 | 0.98 | SIRT6 (0.96) | SIRT6ADRB1MAPTHTR7HTR1A | |
| SCHEMBL27980887 | 0.95 | SIRT6 (0.90) | SIRT6ADRB1MAPTHTR7HTR1A | |
| SCHEMBL942183 | 0.93 | SIRT6 (0.87) | SIRT6ADRB1MAPTHTR7HTR1A | |
| Hydrochloric Acid SCHEMBL7984519 | 0.92 | SIRT6 (0.84) | SIRT6ADRB1MAPTHTR7HTR1A | |
| Propane SCHEMBL27412411 | 0.92 | SIRT6 (0.84) | SIRT6ADRB1MAPTHTR7HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020128231-A1 | Aryl-indane compounds | EASTMAN CHEMICAL COMPANY | 2002-09-12 | — | — | US | disclosed |
| WO-2002030915-A2 | ARYL-INDANE COMPOUNDS FOR USE AS INHIBITORS OF P-GLYCOPROTEIN MEDIATED TRANSPORT | AVLAN LIMITED (GB) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128231-A1 | Aryl-indane compounds | ABCB1, ABCC1, ABCG2 | SIRT6 2428/4885ADRB1 1664/4885MAPT 3932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.